Skip to main content
OpenTrials
Completed

NCT Number: NCT01459887

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

CD20, the protein which is expressed on the surface of all mature B cells, is active in many B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL), the most frequently occurring subtype of non-Hodgkin lymphomas. In clinical practice, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone combination chemotherapy (CHOP) is still considered one of the standard treatment to DLBCL. CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases. This trial aimed to observe the safety and efficacy of CMAB304, by added CMAB304 to CHOP chemotherapy regimen compared with CHOP chemotherapy alone.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diffuse Large B Cell Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

SUN-YAT-SEN university cancer center

Guangzhou, Guangdong, 510060, China

About this study

Rituximab, a chimeric anti-CD20 monoclonal antibody, has been proved valuable treatment for CD20-positive DLBCL. The combination of rituximab with CHOP has been shown to increase both survival and response rate, in comparison to CHOP alone. CMAB304(Retuxira), a biosimilar of rituximab, was developed by Shanghai CP Guojian Pharmaceutical Co.,Ltd. Previous Phase I study showed that CMAB304 was well tolerated as monotherapy and the pharmacokinetic data exhibited a non-linear profile over the dose range of 250 to 500 mg/m2. In this study, efficacy and safety of CMAB304 were evaluated in DLBCL patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 18 to 70 year, male or female
  • Previously untreated
  • DLBCL patients with CD20-positive
  • Lymphoma lesions can be Measured and evaluated; Spiral CT or MR evaluation of the lesion must be ≥ 1cm; Measured by clinical examination or others must be ≥ 2cm
  • Normal blood test, adequate liver and renal function;
  • ECOG score 0~2
  • Life expectancy of greater than 3 months
  • No other malignancy treatment history, except cured carcinoma in situ of the cervix or squamous cell or basal cell skin cancer
  • Signed ICF

Exclusion criteria

  • DLBCL transformed from other low-grade NHL types
  • Primary central nervous system lymphoma, or primary gastrointestinal DLBCL
  • History of foreign protein allergies
  • Abnormal liver and/or renal function
  • Suspected or diagnosed central nervous system violation
  • Serious infection or organic diseases
  • Heart disease, heart failure, heart block above second degree, myocardial infarction occurred within six months
  • Breastfeeding or pregnant
  • Leukemia crisis or bone marrow metastases

Treatment and study plan

CHOP combined with CMAB304

Drug

Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.

Other names: cyclophosphamide, doxorubicin, vincristine, prednisone

CHOP, CMAB304

Drug

First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.

Other names: cyclophosphamide, doxorubicin, vincristine, prednisone

Primary outcomes

  1. overall response rate

    Time frame: up to 18 weeks

    Tumor responses were assessed after 6 cycles of CMAB304-CHOP or 6 cycles of CHOP alone and classified as CR,CRu,PR,SD or PD.

Secondary outcomes

  1. event-free survival

    Time frame: From date of randomization until the date of first documented progression or relapse, institution of a new anticancer treatment, or death from any cause, whichever came first, assessed up to 50 months

    Events were defined as disease progression or relapse, institution of a new anticancer treatment, or death from any cause.

Sponsors and collaborators

Lead sponsor

Shanghai CP Guojian Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL

Important dates

Study start
2006
Primary completion
2010
Study completion
2011
First posted
Oct 26, 2011
Registry last updated
Oct 26, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.